Prospective evaluation of the impact of potent antiretroviral therapy on the incidence of Kaposi’s Sarcoma in East Africa: findings from the International Epidemiologic Databases to Evaluate AIDS (IeDEA) Consortium
![Thumbnail](/xmlui/bitstream/handle/123456789/3255/Prospective%20evaluation%20of%20the%20impact%20of%20potent%20antiretroviral%20therapy%20on%20the%20incidence%20of%20Kaposi%e2%80%99s%20Sarcoma%20in%20East%20Africa-%20findings%20from%20the%20International%20Epidemiologic%20Databases%20to%20Evaluate%20AIDS%20%28IeDEA%29%20Consortium.pdf.jpg?sequence=4&isAllowed=y)
View/ Open
Date
2012Author
Martin, Jeffrey
Wenger, Megan
Busakhala, Naftali
Buziba, Nathan
Bwana, Mwebesa
Muyindike, Winnie
Mbabazi, Ruth
Amerson, Erin
Yiannoutsos, Constantin
Musick, Beverly
LeBoit, Philip
McCalmont, Timothy
Ruben, Beth
Maurer, Toby
Wools-Kaloustian, Kara
Metadata
Show full item recordAbstract
Prior to the rollout of potent antiretroviral therapy (ART), Kaposi’s sarcoma (KS) was the most commonly reported malignancy in many resource-limited settings, such as most of sub-Saharan Africa. In resource-replete settings (e.g., U.S. or Europe), the advent of ART—and the availability of established research networks— resulted in documentation of a marked decrease in KS incidence. In contrast, in resource-limiting settings like Africa, the heretofore lack of epidemiologic infrastructure has limited our knowledge about the effect of ART on KS incidence.
Collections
- Research Articles [109]